Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence

BACKGROUND AND PURPOSE: Chronic migraine is a highly disabling primary headache disorder that is the most common diagnosis of patients seen at tertiary headache centres. Typical oral preventive therapies are associated with many limitations that impact their therapeutic utility. Erenumab was the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Modar, Moreno‐Ajona, David, Villar‐Martínez, María Dolores, Greenwood, Fiona, Hoffmann, Jan, Goadsby, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Headache
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545124/
https://www.ncbi.nlm.nih.gov/pubmed/35445471
http://dx.doi.org/10.1111/ene.15364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545124/
https://www.ncbi.nlm.nih.gov/pubmed/35445471
http://dx.doi.org/10.1111/ene.15364

Ejemplares similares